Ind-Swift Laboratories — 360° view

Ind-Swift Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹240 crore and net profit of ₹34 crore for the September 2026 quarter.

Ind-Swift Laboratories (NSE: INDSWFTLAB) closed at ₹317.05 on 20 Nov 2026, up 232.7% over the past year. Its market capitalisation is ₹2,757 crore and it trades at 30.1 times earnings.

Share price
₹317.05 (20 Nov 2026)
Market cap
₹2,757 Cr (20 Nov 2026)
P/E
30.05 (20 Nov 2026)
Revenue
₹240 Cr (September 2026 quarter)
Net profit
₹34 Cr (September 2026 quarter)
ROCE
4.86% (FY26)
ROE
4.02% (FY26)
Book value
₹170 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹426.60 / ₹87.15 (20 Nov 2026)
1-year return
232.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: INDSWFTLAB

Incorporated in 1995, Ind-Swift Laboratories Ltd is a pharmaceutical company focused on finished dosage formulations (FDF). Co. manufactures tablets, capsules, ointments, injectables, liquids and dry syrups across therapies including gynaecology, paediatrics, cardiology, diabetology and dermatology. Operations span domestic formulations and international markets through own brands, contract manufacturing and out-licensing.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.